Daxor Corp
DXR
Company Profile
Business description
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
Contact
107 Meco Lane
Oak RidgeTN37830
USAT: +1 212 330-8500
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
750
Stocks News & Analysis
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
stocks
Wide moat healthcare leader remains undervalued
ASX healthcare giant expected to see uptick in demand from emerging markets.
stocks
This US AI winner has been unstoppable. Is it time to sell?
Astonishing results have driven this AI stock into significantly overvalued territory.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,855.90 | 79.60 | -0.89% |
| CAC 40 | 8,218.24 | 26.05 | -0.32% |
| DAX 40 | 24,759.05 | 185.90 | -0.75% |
| Dow JONES (US) | 51,134.69 | 427.24 | -0.83% |
| FTSE 100 | 10,368.05 | 7.73 | 0.07% |
| HKSE | 24,961.95 | 291.45 | -1.15% |
| NASDAQ | 26,037.61 | 793.35 | -2.96% |
| Nikkei 225 | 66,588.12 | 882.57 | -1.31% |
| NZX 50 Index | 13,161.97 | 60.36 | 0.46% |
| S&P 500 | 7,450.81 | 133.50 | -1.76% |
| S&P/ASX 200 | 8,625.10 | 80.00 | -0.92% |
| SSE Composite Index | 4,027.74 | 30.04 | -0.74% |